In today’s briefing:
- Intel’s Next CEO Will Have To Deal With An Unholy Mess. But Who Will It Be?
- Ainos, Inc.- Signed Veldona Partner for Manufacturing and Taiwan Marketing of Sjogren’s Drug
- ECVT: Unlocking of Value
- TELO: Another Potential Breakthrough
- VRA; 3Q Preview: Learning and Moving Forward; Reiterate Buy, $6 Price Target
- VNRX: Reports 3Q 2024 results. Over 110
- ADEA: AMZN License Announced
- Zephyr Energy Plc (AIM: ZPHR): FY24 production guidance re-iterated. Binding agreement with Paradox partner by YE24
- MTVA: NeuroBo Becomes MetaVia Topline Results for Phase 2a
- Ocean Power Technologies, Inc. – Delivers Strong 2QFY25
Intel’s Next CEO Will Have To Deal With An Unholy Mess. But Who Will It Be?
- Gelsinger’s IDM 2.0 strategy will be up for debate by Intel’s BoD. Most likely it will be largely scaled back
- The new CEO’s options will be limited by the legal agreements in place with Brookfield & Apollo, along with the restrictions imposed by the US DOC
- Possible CEO candidates are the current Globalfoundries CEO, Tom Caulfield, former Intel board member Lip-Bu Tan and former Intel executive Stacy Smith, who recently joined Intel’s BoD
Ainos, Inc.- Signed Veldona Partner for Manufacturing and Taiwan Marketing of Sjogren’s Drug
- Key regional partner for Veldona; a good start for Ainos’ out-licensing strategy.
- Ainos entered a strategic partnership with Taiwan Tanabe Seiyaku for Veldona in Sjogren’s syndrome.
- Under a memorandum of understanding (MOU), the collaboration aims to advance Veldona development by leveraging Taiwan Tanabe’s established expertise in drug manufacturing and Taiwan market promotion.
ECVT: Unlocking of Value
- ECVT has gone through several business divestments and acquisitions over its history and the latest news suggests management is not content.
- The timing is a surprise given the segment is to serve ECVT’s growth trajectory. The segment houses new technologies that should begin to contribute to sales in coming quarters.
- Advanced materials and catalysts is also the segment that owns the 50% stake in JV Zeolyst, which has been core of issues this year related to ECVT’s adjusted EBITDA performance.
TELO: Another Potential Breakthrough
- Telomir Pharmaceuticals is a preclinical stage company focused on the science of lengthening telomere caps, which the company believes will extend human lifespans and improve quality of life as people age.
- Preclinical tests showed that the company’s signature therapy, Telomir-1, appeared to address insulin resistance and achieving reversal to near pre-diabetic levels.
- These results add to previous testing results showing a myriad of potential life improving and extending benefits.
VRA; 3Q Preview: Learning and Moving Forward; Reiterate Buy, $6 Price Target
- We are reiterating our Buy rating, $6 price target and projections for Vera Bradley with the company announcing 3QFY25 (October) results before the open on Wednesday.
- We believe 3Q, the first full quarter of operations after the relaunch of the Vera Bradley brand in both the main line and outlet stores, remained a key learning experience, as management, after dramatically shifting the entire main line store and materially changing the outlets, begins to calibrate feedback to maximize the shifts and begin to attract a wider customer base.
- While we remain cautious in our projections in the nearer term, we believe the shifts will help revive Vera Bradley and drive strong returns in the longer term.
VNRX: Reports 3Q 2024 results. Over 110
- Volition’s Nu.Q Vet Canine Cancer Screening Test now available in 17 countries, particularly by Antech on its Element I+ diagnostic point-of-sale platform (in the U.S., Europe, Australia, India & Singapore) and by Fujifilm Vet Systems (Japan).
- A Data Room that contains all clinical studies and other data related to Capture-PCR (human cancer detection method) and Nu.Q NETs for human sepsis has been set up to support licensing discussions and negotiations with interested parties.
- Research continues on developing biomarkers for multiple cancers in proof of concept studies.
ADEA: AMZN License Announced
- ADEA announced a licensing agreement with AMZN setting the path for greater free cash flow in 2025. ADEA has previously mentioned it was close to signing two major licensing agreements.
- We assume ADEA’s full year guidance includes catch-up revenue associated with the license since AMZN was never a licensee before.
- ADEA had already signed several video streaming licenses, but AMZN would serve as the largest to date. It gives the investment story a stronger foundation.
Zephyr Energy Plc (AIM: ZPHR): FY24 production guidance re-iterated. Binding agreement with Paradox partner by YE24
- • 3Q24 production was 1,047 boe/d.
- Zephyr has re-iterated its FY production guidance of 1,100-1,300 boe/d.
- We are cautiously assuming 1,100 boe/d.
MTVA: NeuroBo Becomes MetaVia Topline Results for Phase 2a
- On November 18, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced a strategic realignment with a name change to MetaVia Inc. (MTVA).
- The change became effective on November 29, 2024.
- We are republishing the latest research report under the MTVA ticker.
Ocean Power Technologies, Inc. – Delivers Strong 2QFY25
- OPT reported preliminary 2QFY25 results and reaffirmed previous guidance of achieving profitability in 4Q25.
- The company expects 2QFY25 revenue to come in at more than $2.0 million compared with $0.9 million in 2QFY24.
- Net loss is expected to be lower at ~$4.0 million compared with $7.2 million last year, driven by a 40% reduction in operating expenses due to lower third-party spending and higher revenue.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
